



## IN LICENSING OPPORTUNITY

## Mixed Amphetamine Extended Release Capsules Bioequivalent to Adderall XR®

Product overview and general licensing terms

### Delayed-release 12-h mixed amphetamine once-a-day capsules

dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate

**Indication**  
ADHD

**Reference product**  
Adderall XR® (Shire)

**Strengths**  
5, 10, 15, 20, 25 and 30 mg

Bioequivalence to Adderall XR® demonstrated in fed and fasting conditions for D and R salts.


### Stage of development

## Ready to transfer to licensee facility

Formulation fully proportional from 5 mg to 30 mg with biphasic release profile

- Bioequivalence to Adderall XR® demonstrated in human trials
- Exhibit batch manufacturing completed
- Accelerated and long-term stability supporting 24-month shelf life on filing

Human PK versus Adderall XR® | Fasting conditions



**Exclusivity**  
Territory-specific  
Licensees

### General terms

- Upfront licensing fee
- Development, regulatory and sales milestones
- Royalties on net sales

### Next steps

- Seeking term-sheets from interested parties

